Global Orphan Drugs Market: Snapshot
The increasing focus on the improvement of the healthcare infrastructure and medical sector are estimated to encourage the growth of the orphan drugs market over the next few years. As per the research study by TMR, the global market for orphan drugs is predicted to reach a value of US$318.5 bn by 2025. The market is expected to register 12.10% CAGR between 2017 and 2025.
Rising Cases of Cancer to Propel Orphan Drugs Market in Coming Years
The rise in the number of cancer patients and the high growth of the oncology segment are the major factors that are projected to ensure the enhancement of the orphan drugs market in the coming few years. The discovery of different types of rare cancers and the development of early diagnostic techniques are further projected to encourage the growth of the market in the next few years. The rising focus of the players on research activities are expected to boost the growth of the orphan drugs market in the next few years. In addition to this, the rising cases of metabolic and cardiovascular are likely to boost the demand for orphan drugs in the next few years.
On the other hand, the high cost of development of drugs is one of the major factors that is estimated to inhibit the growth of the overall orphan drugs market in the coming years. Moreover, the lack of awareness among people regarding the availability of drugs and treatments are estimated to curtail its growth in the coming years. Nevertheless, the rising number of government initiatives and the increasing investments by the key players are projected to offer lucrative opportunities over the next few years.
High Research Activities to Support Growth across North America Orphan Drugs Market
The presence of a well-established healthcare infrastructure is anticipated to encourage the development of the orphan drugs market across North America in the coming few years. The favorable rules and regulations related to the approval of drugs for rare disorders and the rising initiatives by non-governmental and governmental agencies in order to raise awareness among people are expected to ensure the development of the market in the near future. In addition to this, the growing focus of the players on the research and development activities is predicted to support the growth of the market in the coming years.
The global market for orphan drugs is expected to have a competitive environment among the prominent players that are operating worldwide. The rise in the number of players that are projected to enter the market over the next few years is likely to add to the competitiveness. In the last few years, there has been a tremendous rise in the development of drugs and the rapid development of biopharmaceutical sector are estimated to support the growth of the market in the coming few years. In addition to this, the increasing investments by the key players for the research activities is predicted to generate growth opportunities, thus accelerating the growth of the overall market in the next few years. The prominent players engaged in the orphan drugs market across the globe are Johnson & Johnson, Alexion Pharmaceuticals Inc., Amgen Inc., F. Hoffmann-La Roche Ltd., AstraZeneca plc., Bayer AG, GlaxoSmithKline plc., Shire plc., Eisai Co. Ltd., Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., and Celgene Corporation.
Orphan Drugs Market: Overview
The underlying reasons that are fuelling demand for orphan drugs are the increasing occurrences of rare diseases. During forecast timeframe of 2017 to 2025, the world market for orphan drugs is prognosticated to register a robust rate of growth, and the same is supported by several factors like sound research and development for orphan drugs especially in the developed economies, growing incidences of rare diseases, and high return on investments (ROI) that can be obtained for the invention and development of these drugs.
Considering the vendor landscape, the market for orphan drugs is considered to be reasonably fragmented and the market players emphasize on strategically important acquisitions. The companies are also more focused on taking advantage of the various incentives that are been provided by the governments to encourage research and development work on orphan drugs.
Orphan Drugs Market: Trends and Opportunities
In many developed economies such as the United States, the United Kingdom (the U.K.) intense focus on research and development work on orphan drugs begets fee waivers, government benefits, and tax credits and are as such contributing towards market growth. According to Research Office Legislative Council Secretariat, around 30 million people are suffering from some form of rare diseases or the other in the United States. As such, a total number of 4171 drugs have been given the status of orphan drug in the United States. Such initiatives by the government are encouraging the manufacturers of such drugs to make more investments in the said market.
In addition to that, soaring incidences of many types of unusual illness that are associated with various genetic reasons result in investments for drug development for these uncommon diseases. Such investments are proving to be advantageous for the market for orphan drugs. As per the data of a non-profit organization, Global Genes, more than 7,000 kinds of uncommon diseases have been detected worldwide. Presently, around 300 million individuals across the globe are forecasted to be attacked by some rare diseases and such high figures demand for substantial amount of manufacturing of orphan drugs.
Orphan Drugs Market: Geography
Taking geographical segmentations into consideration, the international market for orphan drugs is divided into Europe, North America, and Rest of the World. In the year 2016, the region of North America accounted for lion’s share of the said market owing to several factors that such as encouraging regulations that facilitate speedy approval of such drugs, exclusivity of the drug status that are meant for such drugs, and prevailing robust medical infrastructure all contribute towards the growth of the market.
The country of United States, North America, makes substantial contribution towards this market since around 30 million American people are reportedly affected with some form rare disease of the other. Such high occurrences of rare diseases demand sound research and development work for the purpose of development of better orphan drugs.
Orphan Drugs Market: Company Profiling
Amgen Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Alexion Pharmaceuticals Inc., Novo Nordisk A/S, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc. are some of the topnotch players of this market. The leading companies account a major share of the market, making it very difficult for new players to enter the market.
For the purpose of this study, the market has been segmented as follows:
- Global Orphan Drugs Market, by Disease Type
- Metabolic disorders
- Infectious diseases
- Global Orphan Drugs Market, by Indicator
- Global Orphan Drugs Market, by Technology
- Hospital Pharmacies
- Specialty Pharmacies
- Retail pharmacies
- Global Orphan Drugs Market, by Geography
- North America
- Rest of Europe
- Rest of the World
- South Korea